VIDEO: ADAPT finding ‘continues to open the door’ to de-escalation
Click Here to Manage Email Alerts
In this video, Erica L. Mayer, MD, MPH, an assistant professor of medicine at Harvard Medical School and a director of clinical research at Dana-Farber Cancer Institute, discussed results from the ADAPT HER2 study presented at ASCO 2021.
“The ADAPT platform is a very innovative and flexible platform through which the West German Study Group has looked at many different and important questions in breast cancer management,” Mayer said. “This presentation focused on HER2-positive breast cancers and randomized patients to receive THP, so weekly paclitaxel, trastuzumab and pertuzumab vs. HP alone, so two antibodies and no chemotherapy used.”
She noted that patients included in the study, overall, had “favorable” cancer prognoses, and were strongly HER2-positive.
“What was very interesting was that the pCR rate seen in those that receive the THP was astounding — close to 90% — so a very high pCR rate,” Mayer said. “And very importantly, that supports and continues to open the door toward the concept of treatment de-escalation.
“If we can get such a high [pCR] rate with using weekly chemotherapy for 12 weeks with HP, perhaps we don’t need the complicated multi-drug regimens that have been previously invoked in this setting.”
Mayer said that additional studies, including the ongoing COMPASS HER2 trial, will provide additional data on the long-term efficacy of this strategy.
Collapse
Read more about
Click Here to Manage Email Alerts